Core Insights - Alphon Capital is leveraging blockchain technology to fund cancer research through asset tokenization, aiming to merge digital assets with biotech innovations [1][7][10] - The integration of blockchain is seen as a way to accelerate funding for biotech projects, particularly in the context of cancer research, which traditionally faces funding challenges [9][10][15] Company Overview - Alphon Capital focuses on the Telegram ecosystem, which has over a billion users, and aims to create revenue-generating businesses within this space [2][18] - The company is a rebrand of Portage Biotech and is involved in developing novel cancer therapies, with one molecule already in phase one clinical trials [7][8] Blockchain Integration - The positive shift in US regulations is driving institutional adoption of blockchain technologies, with companies like Telegram leading the way [4][5] - Tokenization is expected to revolutionize funding mechanisms for biotech, allowing for quicker capital raises compared to traditional methods [10][12] Financial and Scientific Goals - Alphon aims to be a growth vehicle for various revenue-producing businesses across the Telegram ecosystem, including gaming, DeFi, and healthcare applications [17][18] - The company has invested in a large treasury of Ton tokens to strengthen its balance sheet and create demand for the token within its business model [19]